



Press Release

ONCOLYS BIOPHARMA INC.

(TSE Mothers: 4588)

10 July 2017

Yasuo Urata, President & CEO of Oncolys BioPharma to Present at the 23rd Annual Meeting of JSGCT

Tokyo, JAPAN: Oncolys BioPharma (“Oncolys”) is pleased to announce that Yasuo Urata, President and CEO of the company, is to join Luncheon Seminar as a member of the panel at the 23rd Annual Meeting of Japan Society of Gene and Cell Therapy (“JSGCT”) which takes place at Okayama Convention Center in Okayama Prefecture from Thursday 20th to Sunday 22nd July 2017.

During the seminar titled “Toward Practical Operation of “Cartagena Act” in Gene Therapy”, a panel of experts in gene therapy with academic and business backgrounds, with each giving a brief presentation, will discuss issues related to genetically modified DNAs and on the way how to smooth the path to industry-academia cooperation.

Details of the luncheon seminar are as below:

【Panel Luncheon Seminar - The 23rd Annual Meeting of JSGCT】

Time & Date: Thu 20 July 2017, 12:00 – 13:00 (Corporate Seminar II)

Venue: Hall B, Okayama Convention Center, Okayama Prefecture, Japan

Theme: Toward Practical Operation of “Cartagena Act” in Gene Therapy

Moderator: Masafumi Onodera, MD, PhD, Head, Department of Human Genetics, National Center for Child Health and Development

Speakers:

1) Takashi Kojima, MD, Head, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East.

“From the View Point of Conducting Investigator-initiated trials”

2) Yasuo Urata, President and CEO, Oncolys BioPharma Inc.

“From the View Point of Conducting Sponsor-initiated trials”

3) Akihiko Kume, MD, PhD, Professor, Support Center for Clinical Investigation, Jichi Medical University
“From the View Point of Translation between Academia, Industry and Regulatory Agencies”

For more information, please visit the website: <http://www.med-gakkai.org/jsjgct23/>

###

About Oncolys BioPharma Inc.:

Oncolys BioPharma is a TSE Mothers-listed biopharmaceutical company with focuses on the development of novel biologics for the treatment of cancer and infectious diseases. The company’s lead product for the treatment of cancer, Telomelysin® (OBP-301), is based on replication-competent oncolytic virus, and is being tested as monotherapy in Phase I/II clinical trial in Asia and Phase II in the USA, for various solid tumors. In Japan, while Oncolys successfully enrolled the first patient in its own Phase I clinical trial for Telomelysin-radiation combination therapy in July 2017, an investigator-led clinical trial for Telomelysin-pembrolizumab combination therapy is underway at National Cancer Centre Hospital East. A novel cancer diagnostic product, TelomeScan® (OBP-401/1101), is expected to be effective as companion diagnostic tool in detecting various types of cancer and inflammatory diseases and adopted in several private practices. The company also has a major program OBP-601 (Censavudine) for infectious diseases, for which it completed Phase II clinical trial in the U.S. for HIV/AIDS therapy, supported by BMS.

For more information, please visit <http://www.oncolys.com/en/>

Oncolys BioPharma Inc.

Mie Yamazaki
Investors Relations & Corporate Communications
Tel: +81 (0) 5472 1578
Email: yamazaki@oncolys.com